CELC today
$64.45+$0.13 (+0.20%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourDescending Triangle
1 hourExpanding
15 minBearish
5 minBullish
Daily trend turns up above $76.29
Key levels
Resistance$72.00
Resistance$66.14
Support$53.54
Support$45.03
Latest news & SEC filings
ProductCelcuity says FDA accepted its sNDA for REVTORPYK (gedatolisib)
ProductCelcuity says FDA will review its filing for REVTORPYK in HR-positive disease
AnalystHC Wainwright keeps Buy rating on Celcuity, cuts price target
AnalystHC Wainwright keeps Buy rating on Celcuity, cuts price target to $150
All CELC news →About Celcuity
Celcuity develops experimental medicines that target solid tumors. Its main drug candidate, gedatolisib, is given by infusion and blocks several PI3K proteins along with both mTOR complexes. Testing is underway in advanced breast cancer and prostate cancer, with late-stage trials named VIKTORIA-1 and VIKTORIA-2.
Based on the company's 10-K filed Mar 26, 2026.
Nasdaq · Healthcare
Celcuity Inc. (CELC)
What Is the Price Target for CELC?
SEPT Low Target
$134.00
SEPT Mid Target
$155.00
SEPT High Target
$177.00
Analyst Consensus
$155.00
Is CELC a Buy or Sell Right Now?
Thesis
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for CELC.
Start Free Trial →Is CELC Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$155.00
0
Moat Score
NONE
3/9
Piotroski Score
3.9
Altman Z-Score
What Is Smart Money Doing with CELC?
Insider Signal
SELLING
0 buys / 8 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Furcht Leo | director | Buy | 250 | $2K | Oct 7, 2026 |
| GRYSKA DAVID W | director | Buy | 893 | - | Oct 1, 2026 |
| Murphy Polly A. | director | Buy | 1,530 | - | Jun 5, 2026 |
| ROMP CHARLES R | director | Buy | 1,530 | - | Jun 5, 2026 |
| Furcht Leo | director | Buy | 1,530 | - | Jun 5, 2026 |
| Buller Richard E | director | Buy | 1,530 | - | Jun 5, 2026 |
| Dalvey David | director | Buy | 1,530 | - | Jun 5, 2026 |
| NIGON RICHARD | director | Buy | 1,530 | - | Jun 5, 2026 |
| Laing Lance G. | director officer | Buy | 1,000 | $10K | Jun 2, 2026 |
| Buller Richard E | director | Sale | 1,029 | - | May 19, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →CELC Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
-33.92%
FCF Growth YoY
-83.4%
Revenue Trend
UNKNOWN
Dark Pool Trades for CELC
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for CELC, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 19:13:41 | $65.19 | 1,077 | $$70K | BUY |
| 19:13:41 | $65.06 | 25,000 | $$1.6M | SELL |
| 19:09:23 | $64.66 | 4,986 | $$322K | BUY |
| 18:36:58 | $64.93 | 1,060 | $$69K | BUY |
| 18:33:59 | $64.85 | 1,000 | $$65K | SELL |
5 dark pool trades shown · $$2.2M preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Celcuity Inc. (CELC) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →CELC — frequently asked questions
What is CELC stock price today?
Celcuity Inc. (CELC) is at $64.45, up 0.20% (+$0.13) at the Nov 12, 2026 close.
Why is CELC stock moving today?
Latest CELC news — Nov 9, 2026: Celcuity says FDA accepted its sNDA for REVTORPYK (gedatolisib) · Nov 9, 2026: Celcuity says FDA will review its filing for REVTORPYK in HR-positive disease
What is the CELC price target?
The average analyst price target for CELC is $155.00, ranging from $134 to $177, based on 9 analysts. Latest: Cantor Fitzgerald initiates on Oct 22, 2026.
What do analysts rate CELC?
Analyst ratings for CELC: 2 Buy, 18 Hold, 0 Sell — consensus Hold.
Did CELC beat earnings?
CELC last reported on Aug 13, 2026: EPS -$1.44 vs -$1.16 expected — a miss of 24.1%.
Does CELC pay a dividend?
CELC does not currently pay a dividend.
How much debt does CELC have?
Celcuity Inc. reported $0M of debt and $182M of cash (Jun 30, 2026).
What are CELC support and resistance levels?
Support: $53.54, $45.03, $34.30. Resistance: $66.14, $72.00, $77.07.
What are insiders doing with CELC?
Insider activity: SELLING, 0 buys and 8 sells in the last 90 days.
What is the latest news on CELC?
Nov 9, 2026: Celcuity says FDA accepted its sNDA for REVTORPYK (gedatolisib) · Nov 9, 2026: Celcuity says FDA will review its filing for REVTORPYK in HR-positive disease · Nov 9, 2026: HC Wainwright keeps Buy rating on Celcuity, cuts price target